生物科技公司Compugen(Compugen)报告收入较低, 但获得股票评级升级为“购买”。 Biotech firm Compugen reports lower earnings, yet gets a stock rating upgrade to "buy."

生物技术公司Compugen报告季度收入低于预期,每股0.01美元,没有预测2.21美元的分析师。 Biotech firm Compugen reported a lower-than-expected quarterly earnings of $0.01 per share, missing the analyst forecast of $0.21. 收入为1 713万美元,也低于预计收入1 767万美元。 Revenue was $17.13 million, also falling short of the expected $17.67 million. 尽管收入不足, StockNews.com 将公司的评级从“持有”提升为“购买”。 Despite the earnings miss, StockNews.com upgraded the company’s rating from "hold" to "buy." Compugen侧重于免疫-肿瘤学,几个临床阶段的候选者正在开发中。 Compugen focuses on immuno-oncology with several clinical-stage candidates in development. 其股票价格约为1.60美元。 Its stock price is around $1.60.

文章

Markets Daily

Modern Readers

Kopsource

-- 显示更少 --

延伸阅读

相关故事